149 related articles for article (PubMed ID: 30379089)
1. Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate.
Miyata M; Kuroda M; Unakami M; Tasaki K; Migita K; Ohira H
Mod Rheumatol; 2019 Nov; 29(6):936-942. PubMed ID: 30379089
[No Abstract] [Full Text] [Related]
2. Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index.
Avouac J; Degrave R; Vergneault H; Combier A; Wanono S; Boisson M; Frantz C; Allanore Y
Clin Exp Rheumatol; 2022 Jan; 40(1):150-157. PubMed ID: 33938795
[TBL] [Abstract][Full Text] [Related]
3. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
Lertnawapan R; Chonprasertsuk S; Siramolpiwat S
Int J Rheum Dis; 2019 Feb; 22(2):214-221. PubMed ID: 30565876
[TBL] [Abstract][Full Text] [Related]
4. "Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?".
García DS; Saturansky EI; Poncino D; Martínez-Artola Y; Rosenberg S; Abritta G; Ascimani-Peña C; Cravero A
Ann Hepatol; 2019; 18(5):765-769. PubMed ID: 31105018
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment.
Mori S; Arima N; Ito M; Fujiyama S; Kamo Y; Ueki Y
PLoS One; 2018; 13(8):e0203084. PubMed ID: 30142184
[TBL] [Abstract][Full Text] [Related]
6. Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.
Osuga T; Ikura Y; Kadota C; Hirano S; Iwai Y; Hayakumo T
Int J Clin Exp Pathol; 2015; 8(2):1961-6. PubMed ID: 25973089
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis.
Kim TY; Kim JY; Sohn JH; Lee HS; Bang SY; Kim Y; Kim MY; Jeong WK
J Ultrasound Med; 2015 Sep; 34(9):1621-30. PubMed ID: 26269292
[TBL] [Abstract][Full Text] [Related]
8. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.
Hu YC; Liu H; Liu XY; Ma LN; Guan YH; Luo X; Ding XC
World J Gastroenterol; 2017 Nov; 23(41):7425-7432. PubMed ID: 29151696
[TBL] [Abstract][Full Text] [Related]
9. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system.
Richard S; Guerret S; Gerard F; Tebib JG; Vignon E
Rheumatology (Oxford); 2000 Jan; 39(1):50-4. PubMed ID: 10662873
[TBL] [Abstract][Full Text] [Related]
10. Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate.
Olsson-White DA; Olynyk JK; Ayonrinde OT; Paramalingam S; Keen HI
Intern Med J; 2022 Apr; 52(4):566-573. PubMed ID: 33135387
[TBL] [Abstract][Full Text] [Related]
11. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate.
Aponte J; Petrelli M
Arthritis Rheum; 1988 Dec; 31(12):1457-64. PubMed ID: 3196364
[TBL] [Abstract][Full Text] [Related]
13. The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis.
Bjorkman DJ; Boschert M; Tolman KG; Clegg DO; Ward JR
Arthritis Rheum; 1993 Dec; 36(12):1697-701. PubMed ID: 8250989
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms.
Ezhilarasan D
Toxicology; 2021 Jun; 458():152840. PubMed ID: 34175381
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice.
Karlsson Sundbaum J; Eriksson N; Hallberg P; Lehto N; Wadelius M; Baecklund E
Int J Rheum Dis; 2019 Jul; 22(7):1226-1232. PubMed ID: 31012257
[TBL] [Abstract][Full Text] [Related]
16. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate.
Phillips CA; Cera PJ; Mangan TF; Newman ED
J Rheumatol; 1992 Feb; 19(2):229-33. PubMed ID: 1629819
[TBL] [Abstract][Full Text] [Related]
17. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C.
Amorim TG; Staub GJ; Lazzarotto C; Silva AP; Manes J; Ferronato Mda G; Shiozawa MB; Narciso-Schiavon JL; Dantas-Correa EB; Schiavon Lde L
Ann Hepatol; 2012; 11(6):855-61. PubMed ID: 23109448
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis.
Fathi NH; Mitros F; Hoffman J; Straniero N; Labreque D; Koehnke R; Furst DE
J Rheumatol; 2002 Oct; 29(10):2092-8. PubMed ID: 12375317
[TBL] [Abstract][Full Text] [Related]
19. Liver cirrhosis in rheumatoid arthritis patients treated with long-term methotrexate.
Minocha A; Dean HA; Pittsley RA
Vet Hum Toxicol; 1993 Feb; 35(1):45-8. PubMed ID: 8434456
[TBL] [Abstract][Full Text] [Related]
20. Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study.
Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YB; Han KH; Lee SW
Mod Rheumatol; 2020 Jan; 30(1):70-77. PubMed ID: 30557057
[No Abstract] [Full Text] [Related]
[Next] [New Search]
